Patricia Valerio,  —

Articles by Patricia Valerio

DMD Treatment Candidate DYNE-251 Granted FDA Fast Track Status

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Dyne Therapeutics’ DYNE-251 for the treatment of people with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 51 skipping. Fast track status is intended to accelerate a therapy’s development and expedite…